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Background: Patients with a pathological complete response (pCR) after neoadjuvant chemoradio-
therapy (nCRT) for oesophageal cancer may benefit from non-surgical management. The aim of this
study was to determine the diagnostic performance of visual response assessment of the primary tumour
after nCRT on T2-weighted (T2W) and diffusion-weighted (DW) MRI.
Methods: Patients with locally advanced oesophageal cancer who underwent T2W- and DW-MRI
(1⋅5T) before and after nCRT in two hospitals, between July 2013 and September 2017, were included
in this prospective study. Three radiologists evaluated T2W images retrospectively using a five-point
score for the assessment of residual tumour in a blinded manner and immediately rescored after
adding DW-MRI. Histopathology of the resection specimen was used as the reference standard; ypT0
represented a pCR. Sensitivity, specificity, area under the receiver operating characteristic (ROC) curve
(AUC) and interobserver agreement were calculated.
Results: Twelve of 51 patients (24 per cent) had a pCR. The sensitivity and specificity of T2W-MRI
for detection of residual tumour ranged from 90 to 100 and 8 to 25 per cent respectively. Respective
values for T2W+DW-MRI were 90–97 and 42–50 per cent. AUCs for the three readers were 0⋅65, 0⋅66
and 0⋅68 on T2W-MRI, and 0⋅71, 0⋅70 and 0⋅70 on T2W+DW-MRI (P= 0⋅441, P=0⋅611 and P= 0⋅828
for readers 1, 2 and 3 respectively). The 𝛋 value for interobserver agreement improved from 0⋅24–0⋅55
on T2W-MRI to 0⋅55–0⋅71 with DW-MRI.
Conclusion: Preoperative assessment of residual tumour on MRI after nCRT for oesophageal cancer is
feasible with high sensitivity, reflecting a low chance of missing residual tumour. However, the specificity
was low; this results in overstaging of complete responders as having residual tumour and, consequently,
overtreatment.
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Introduction
A standard therapy with curative intent for patients with
locally advanced oesophageal cancer consists of neoad-
juvant chemoradiotherapy (nCRT) followed by surgery.
nCRT improves survival compared with surgery alone
(5-year survival rate 47 versus 33 per cent respectively)1.
In 25–30 per cent of patients with oesophageal can-
cer, the resection specimen shows no residual tumour
cells (ypT0) after nCRT2,3, also known as a pathological
complete response (pCR). Patients with a pCR have an
excellent prognosis, with a 5-year recurrence-free survival
rate of 62 per cent4,5, which is better than that of patients
with vital tumour cells in the resection specimen (no
pCR). The high postoperative morbidity and mortality
rates after oesophagectomy raise the question of whether
non-surgical management (watch andwait) is a safe alterna-
tive treatment option in patients with oesophageal cancer
who have a clinical complete response (cCR)6.
To implement non-surgical treatment for advanced
oesophageal cancer it is critical to accurately identify pCR.
CT and fluorodeoxyglucose (FDG) PET/CT are both
inaccurate in discriminating residual disease from pCR
owing to the presence of wall thickening and/or radia-
tion oesophagitis7–13. The same is true for endoscopic
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ultrasonography (EUS), which has an accuracy of only 36
per cent for ypT determination14,15. Endoscopic response
evaluation after nCRT is hampered by the fact that it
provides information only on the luminal side of the
oesophagus16, whereas residual cancer cells are located
beneath the mucosal layer in a subset of patients17,18. Even
deeper bite-on-bite biopsies combined with EUS and
fine-needle aspiration of suspicious lymph nodes yielded
a negative predictive value (NPV) of only 45 per cent
for detecting tumours with a tumour regression grade
(TRG) of 2 or higher11. Previous retrospective cohort
studies19–22 reported on patients with a cCR after neoad-
juvant treatment who did not have surgery but underwent
serial response assessments including endoscopy, EUS,
CT and/or FDG-PET/CT. Among those assessed as
having a cCR who did undergo oesophagectomy, residual
tumour was found in 28–33 per cent of patients19–21.
In a propensity-based matching study22, after a median
follow-up of 51⋅1months, local recurrence had developed
more frequently among patients with a cCR who under-
went a watch-and-wait approach than in those who had
surgical treatment.
The limitations of the current response assessment
tools warrant investigation of other imaging techniques.
In rectal cancer, MRI can aid in the diagnosis of a cCR
after nCRT23,24. Although MRI of the oesophagus is
technically more challenging, owing to oesophageal
motility and motion of the surrounding heart and
diaphragm, advances in technology now enable the
acquisition of high-resolution magnetic resonance (MR)
images. Previous studies25–29 on response prediction
with MRI in oesophageal cancer focused on quantitative
diffusion-weighted (DW) MRI parameters. However,
visual response assessment on T2-weighted (T2W) and
Fig. 1 MRI of a patient with locally advanced oesophageal cancer that showed a pathological complete response to neoadjuvant
chemoradiotherapy
a  T2W sagittal image
      before nCRT
b  T2W transverse image before
       nCRT
c  DW image before nCRT
d  T2W sagittal image
       after nCRT
e  T2W transverse image after
      nCRT
f  DW image after nCRT
Images from a 55-year-old man with a cT3N0 lower oesophageal squamous cell carcinoma, and a complete pathological response after neoadjuvant
chemoradiotherapy (nCRT) and oesophagectomy (tumour regression grade 1, ypT0 N0). a–c T2-weighted (T2W) sagittal (a) and transverse (b) images
before chemoradiotherapy show a hyperintense oesophageal wall, accompanied by a hyperintense signal on diffusion-weighted (DW) imaging (c). d–fT2W
sagittal (d) and transverse (e) images after nCRT show a hypointense oesophageal wall, indicating fibrosis; no high signal remained on the corresponding
DW image (f). Arrows mark (initial) tumour location.
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functional DW-MRI in rectal cancer yielded higher
sensitivity for detecting residual tumour compared with
quantitative assessment30. The performance of visual
response assessment on MRI in oesophageal cancer is as
yet unknown. The aim of this study was to determine
the diagnostic performance of visual response assess-
ment of the primary oesophageal tumour after nCRT on
T2W-MRI and functional DW-MRI.
Methods
Patients diagnosed with locally advanced oesophageal
cancer were enrolled prospectively and data were analysed
retrospectively. The study was approved by the local
medical ethics committees and registered at ClinicalTrials
.gov (NCT02139488 and NCT02125448). Written
informed consent to participate was obtained from the
patients. Patients underwent MRI before and after nCRT
between July 2013 and September 2017. Inclusion criteria
were: biopsy-proven locally advanced, non-metastatic
oesophageal cancer; 5weeks of nCRT (total of 41⋅4Gy in
23 fractions, with weekly administration of carboplatin and
paclitaxel) followed by oesophagectomy; and maximum of
21 days between preoperative MRI and surgery. Patients
were excluded if MRI quality was judged insufficient by at
least two radiologists. Causes of insufficient image quality
were severe motion artefacts leading to blurred T2W
images, and lack of, or only slight, diffusion restriction in
the spleen as a surrogate marker of inadequate DW images.
Image acquisition
Imaging was performed on a 1⋅5-T MRI scanner (Achieva
or Ingenia; Koninklijke Philips, Best, the Netherlands),
using Torso-XL (16 channel) or anterior/posterior
(28 channel) receiver coils respectively (supplied
by Koninklijke Philips). The MRI protocol consisted
of T2Wmultislice turbo spin-echo sequences in transverse
Fig. 2 MRI of a patient with locally advanced oesophageal cancer that showed pathological residual tumour after chemoradiotherapy
and surgery
a  T2W sagittal image
      before nCRT
b  T2W transverse image before
       nCRT
c  DW image before nCRT
d  T2W sagittal image
       after nCRT
e  T2W transverse image after
      nCRT
f  DW image after nCRT
Images from a 78-year-old man with a cT2N0 lower oesophageal adenocarcinoma, who had residual tumour after neoadjuvant chemoradiotherapy (nCRT)
and oesophagectomy (tumour regression grade 5, ypT2N0). T2-weighted (T2W) sagittal (a,d) and transverse (b,e) images before (a,b) and after (d,e) nCRT
both show a hyperintense oesophageal wall. The corresponding b= 800 diffusion-weighted (DW) images before (c) and after (f) nCRT demonstrate a clear
hyperintense signal, highly suspicious for tumour. Arrows mark tumour location.
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(slice thickness 4mm) and sagittal (slice thickness 3mm)
planes. A respiratory navigator was positioned on the
diaphragm, and to reduce motion artefacts, images were
acquired only during expiration31. A DW echo-planar
imaging sequence was acquired in the transverse direction
with b= 0, b= 200 and b= 800 s/mm2, and a slice thickness
of 4mm. The transverse T2W and DW sequences were
angled in identical planes. Detailed MRI sequence param-
eters are provided in Table S1 (supporting information).
Image evaluation
Images were analysed independently by three expert radi-
ologists, who were blinded to tumour characteristics (loca-
tion, histology, TNM stage32) and clinical outcomes. The
radiologists first judged images of the primary tumour area
acquired by T2W-MRI andDW-MRI before nCRT. They
then scored the images obtained byT2W-MRI after nCRT
for the likelihood of residual tumour. Finally, still in the
same reading session, DW-MR images of b= 800 s/mm2
were added and the scoring was repeated. A five-point
confidence level score (CLS) was used, derived from pre-
vious studies in rectal cancer (CLS1, definitely complete
response; 2, probably complete response; 3, inconclusive; 4,
probably residual tumour; 5, definitely residual tumour)23.
MRI criteria
A complete response of the primary tumour on T2W-MRI
was defined by a normalized oesophageal wall or only a thin
hypointense signal (indicating fibrosis) without distortion
Fig. 3 Study flow chart
Patients who underwent MRI before and
after nCRT n= 57
Excluded
 Insufficient T2W-MRI quality n= 1
 Insufficient DW-MRI quality n= 3
Excluded
 No oesophagectomy n= 2
Patients with adequate images
n= 53 (106 scans)
Patients included for response assessment
n= 51 (102 scans)
nCRT, neoadjuvant chemoradiotherapy; T2W, T2-weighted; DW,
diffusion-weighted.
of the wall; on DW-MRI, a complete response of the
primary tumour was defined by the absence of high signal
on images of b= 800 s/mm2 in the irradiated tumour
bed. On T2W-MRI, a residual mass with persistent iso-
intense signal or the presence of mixed hyperintense
and hypointense signals within the tumour bed were
considered signs of residual tumour; on DW-MRI, the
presence of high signal within the tumour bed indi-
cated residual tumour. These criteria are illustrated in
Figs 1 and 2.
Table 1 Patient and tumour characteristics
Hospital 1
(n=32)
Hospital 2
(n=19)
Total
(n=51)
Age (years)* 64 (53–72) 64 (60–68) 64 (56–72)
Sex ratio (M :F) 23 : 9 16 : 3 39 : 12
Tumour location
Upper oesophageal 0 1 1 (2)
Middle oesophageal 3 3 6 (12)
Lower oesophageal 15 11 26 (51)
Gastro-oesophageal junction 14 4 18 (35)
Histological tumour type
Adenocarcinoma 28 14 42 (82)
Squamous cell carcinoma 4 5 9 (18)
Grade of differentiation
Well differentiated 2 0 2 (4)
Moderately differentiated 15 10 25 (49)
Poorly differentiated 14 3 17 (33)
Undifferentiated 0 2 2 (4)
Unknown 1 4 5 (10)
Clinical T category†
cT1 1 0 1 (2)
cT2 8 4 12 (24)
cT3 23 14 37 (73)
cT4a 0 1 1 (2)
Clinical N category†
cN0 15 4 19 (37)
cN1 6 8 14 (27)
cN2 9 7 16 (31)
cN3 2 0 2 (4)
Radicality of resection
R0 32 18 50 (98)
R1 0 1 1 (2)
Mandard grade
TRG 1 6 6 12 (24)
TRG 2 10 7 17 (33)
TRG 3 12 4 16 (31)
TRG 4 3 1 4 (8)
TRG 5 1 1 2 (4)
Values in parentheses are percentages unless indicated otherwise; *values
are median (i.q.r.). †According to the seventh edition of the TNM
classification32. Hospital 1, Netherlands Cancer Institute; hospital 2, Uni-
versity Medical Center Utrecht. TRG, tumour regression grade.
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Fig. 4 Receiver operating characteristic curves for assessment of residual tumour after neoadjuvant chemoradiotherapy using
T2-weighted MRI and T2-weighted combined with diffusion-weighted MRI
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a  Radiologist 1 b  Radiologist 2 c  Radiologist 3
a Reader 1, b reader 2 and c reader 3. T2W, T2-weighted; DW, diffusion-weighted. Comparison of areas under the curve for T2W-MRI versus
T2W+DW-MRI: a P= 0⋅441, b P= 0⋅611, c P= 0⋅828 (DeLong test33).
Table 2 Diagnostic performance for assessment of residual tumour
T2W-MRI T2W+DW-MRI
Reader 1 Reader 2 Reader 3 Reader 1 Reader 2 Reader3
Sensitivity (%) 100 90 90 95 97 90
(89, 100) (75, 97) (75, 97) (81, 99) (85, 100) (75, 97)
Specificity (%) 8 25 25 50 42 42
(0, 40) (7, 57) (7, 57) (22, 78) (17, 71) (17, 71)
PPV (%) 78 80 80 86 84 83
(64, 88) (64, 90) (64, 90) (71, 94) (70, 93) (68, 92)
NPV (%) 100 43 43 75 83 56
(6, 100) (12, 80) (12, 80) (36, 96) (37, 99) (23, 85)
True-positive 39 35 35 37 38 35
False-positive 11 9 9 6 7 7
True-negative 1 3 3 6 5 5
False-negative 0 4 4 2 1 4
Accuracy (%) 78 75 75 84 84 78
AUC* 0⋅65 0⋅66 0⋅68 0⋅71 0⋅70 0⋅70
(0⋅47, 0⋅83) (0⋅49, 0⋅83) (0⋅51, 0⋅86) (0⋅52, 0⋅90) (0⋅52, 0⋅88) (0⋅51, 0⋅88)
Values in parentheses are 95 per cent confidence intervals. Residual tumour (tumour regression grade 2–5 in resected primary tumour) was considered
the positive outcome. T2W, T2-weighted; DW, diffusion-weighted; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the
receiver operating characteristic curve. *Comparison of T2W-MRI versus T2W+DW-MRI: P= 0⋅441, P= 0⋅611 and P= 0⋅828 for readers 1, 2 and 3
respectively (DeLong test33).
Reference standard
Histopathological examination of the resection specimen
was performed by dedicated gastrointestinal pathologists
at the two centres. The resection specimen was evaluated
in accordance with the seventh edition of the UICC
protocol for ypTNM classification32. The TRG of the
resected primary tumour was assessed according to Man-
dard and colleagues3. The tumour bed was embedded
completely for histopathological analysis. A pCR was
defined as ypT0 (TRG 1) and residual tumour as ypT1–4
(TRG 2–5).
Statistical analysis
Before undertaking the analyses, dichotomization
between CLS2 (probably complete response) and CLS3
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 596–605
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(inconclusive) was decided as the cut-off, to minimize
the risk of missing residual disease. Receiver operating
characteristic (ROC) curves were constructed and areas
under the curve (AUCs) calculated to evaluate the perfor-
mance of the three radiologists on T2W-MRI only and on
T2W+DW-MRI, with histologically confirmed residual
tumour as the positive outcome. Sensitivities, specifici-
ties, positive predictive values (PPVs) and NPVs were
calculated with 95 per cent confidence intervals. AUCs
on T2W-MRI and T2W+DW-MRI were compared
by means of the DeLong test33. P< 0⋅050 was considered
statistically significant. The possible change in the number
of uncertainties was analysed by comparing the number of
equivocal scores (CLS3). Interobserver agreement between
radiologists was calculated using quadratic weighted κ val-
ues (0–0⋅20, poor; 0⋅21–0⋅40, fair; 0⋅41–0⋅60, moderate;
0⋅61–0⋅80, good; and 0⋅81–1⋅00 excellent agreement)34.
Statistical analyses were done using SPSS® version 22
(IBM, Armonk, New York, USA) and Stata® version 11
(StataCorp, College Station, Texas, USA).
Results
Six of 57 patients were excluded: four had insufficient MRI
quality, one patient had distant metastases after completion
of nCRT and therefore did not undergo surgical resection,
and one patient was deemed to have unresectable disease
at surgical exploration. Therefore, 51 patients were evalu-
ated (Fig. 3). Of the 51 included patients, 42 (82 per cent)
were diagnosed with adenocarcinoma and nine (18 per
cent) with squamous cell carcinoma. Table 1 shows base-
line patient and tumour characteristics at both institutes
that participated in the study. Transhiatal oesophagectomy
was performed in 24 patients (47 per cent) and trans-
thoracic oesophagectomy in 27 (53 per cent), followed by
gastric conduit reconstruction with cervical anastomosis in
all patients. The median interval between the last radiation
fraction and oesophagectomy was 59 (range 24–75) days.
It was 47 (17–65) days between the last radiation fraction
and MRI, and 11 (4–21) days from post-nCRT MRI until
oesophagectomy.
On histopathological assessment, a pCR of the primary
tumour (ypT0, TRG 1) was found in 12 of 51 patients
(24 per cent). In one of these patients, the disease was
confirmed as ypT0N1, which was regarded a complete
response of the primary tumour area (ypT0) in this
study. The pCR rate was five of nine (56 per cent) for
squamous cell carcinomas and seven of 42 (17 per cent)
for adenocarcinomas. The remaining 39 patients had
residual tumour, which was graded as TRG 2 in 17 of
51 patients (33 per cent), TRG 3 in 16 (31 per cent),
TRG 4 in four (8 per cent) and TRG 5 in two patients
(4 per cent).
Diagnostic performance
ROC curves for the assessment of residual tumour after
nCRT are shown in Fig. 4. AUCs on T2W-MRI were
0⋅65 for reader 1, 0⋅66 for reader 2 and 0⋅68 for reader 3.
After addition of DW-MRI, AUCs were 0⋅71, 0⋅70 and
0⋅70 respectively (P= 0⋅441, P= 0⋅611 and P= 0⋅828). The
sensitivity for detection of residual tumour ranged from
90 to 100 per cent on T2W-MRI alone, and from 90 to
97 per cent after addition of DW-MRI. Specificity ranged
from 8 to 25 per cent on T2W-MRI alone, and from 42
to 50 per cent after addition of DW-MRI (Table 2). The
numbers of MRI-positive and -negative tests per TRG
stage for response assessment on T2W+DW-MRI are
shown in Table 3.
Equivocal (confidence level 3) scores
Readers 1, 2 and 3 assigned 16, 30 and 15 equivocal scores
(CLS3) respectively on T2W-MRI, which decreased to 9,
11 and 9 equivocal scores after the addition of DW-MRI.
Table 3 Number of test-positive and test-negative patients according to tumour regression grade for response assessment on
T2-weighted combined with diffusion-weighted MRI
No. of patients
Reader 1 Reader 2 Reader 3
Mandard grade MRI-positive MRI-negative MRI-positive MRI-negative MRI-positive MRI-negative
TRG 1 6 6 7 5 7 5
TRG 2 16 1 16 1 15 2
TRG 3 15 1 16 0 14 2
TRG 4 4 0 4 0 4 0
TRG 5 2 0 2 0 2 0
TRG, tumour regression grade according to Mandard and colleagues3; MRI-positive, clinical residual tumour; MRI-negative, clinical complete response.
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Fig. 5 MRI of a patient with locally advanced oesophageal cancer located at the gastro-oesophageal junction
a  T2W sagittal image
      before nCRT
b  T2W transverse image before
       nCRT
c  DW image before nCRT
d  T2W sagittal image
       after nCRT
e  T2W transverse image after
      nCRT
f  DW image after nCRT
Images from an 80-year-old man with a cT3N0 squamous cell carcinoma located at the gastro-oesophageal junction. Histopathology after oesophagectomy
showed residual tumour (tumour regression grade 2, ypT1a N0). a–c T2-weighted (T2W) sagittal (a) and transverse (b) images before neoadjuvant
chemoradiotherapy (nCRT) show a thick hyperintense wall, accompanied by a hyperintense signal on diffusion-weighted (DW) imaging (c). d–f After
nCRT, the T2W images (d,e) show shrinkage of the wall with a mixed hyperintense and hypointense signal, which was assigned a confidence level score
of 3 by all readers. The DW image (f) shows spots of hyperintense signal in the primary tumour area (arrow), which is suspicious for residual tumour
and was therefore assigned a confidence level score of 4 by all readers. The area within the circle indicates normal stomach wall, which also shows small
hyperintense areas on DW imaging. Arrows indicate tumour location.
Fig. 5 shows an example of a tumour for which all read-
ers assigned an equivocal score on T2W-MRI, whereas a
correct diagnosis of residual tumour (CLS4 for all 3 read-
ers) was made after addition of DW-MRI.
Interobserver agreement
Interobserver agreement was fair to moderate on T2W-
MRI alone (quadratic weighted κ = 0⋅24, 0⋅55 and 0⋅41),
and increased to moderate to good on T2W+DW-MRI
(quadratic weighted κ = 0⋅55, 0⋅71 and 0⋅61).
Discussion
This study has shown that preoperative response assess-
ment after nCRT for oesophageal cancer performed
visually on (DW-)MRI has promising overall diagnostic
performance, with AUCs in the range 0⋅65–0⋅71. The sen-
sitivity of DW-MRI for detection of residual tumour was
high (over 90 per cent), indicating that the chance of miss-
ing residual tumour was small. Addition of images obtained
by functional DW-MRI to the anatomical T2W-MRI pro-
tocol did not influence the overall diagnostic performance
to a great extent, but had a positive impact on the specificity
and NPV for most readers. Moreover, addition of DW
sequences led to improved interobserver agreement and a
reduction in the number of equivocal scores, indicating
increased confidence of the readers. MRI showed promis-
ing visualization of the primary oesophageal tumour bed
after nCRT in oesophageal cancer and could thereby
improve current response assessment strategies. The main
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 596–605
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drawback was the poor specificity of MRI in this unimodal
approach, which in clinical practice would result in over-
staging of complete responders as having residual tumour
and, consequently, overtreatment. Therefore, exploration
of response assessment including MRI, but also other
diagnostic modalities, after nCRT for locally advanced
oesophageal cancer is warranted.
The present study evaluated oesophageal MRI for the
assessment of complete response of the primary tumour
by visual interpretation of morphology on T2W-MRI and
restrictive signals on DW-MRI. Previous studies26,27,29 on
this subject did not perform visual assessment, but focused
on quantitative DW-MRI. These studies found that an
increase in the apparent diffusion coefficient (ADC, a
quantitative measure of the magnitude of diffusion) dur-
ing nCRT, compared with before nCRT, is a predictor of
response. Furthermore, an increase in ADC after nCRT
compared with the baseline value seemed to be predictive
of gross tumour response, defined as TRG 1–228,29 or
TRG 1–325. However, the results reported for the pre-
operative selection of complete response (TRG 1 only)
using ADC values were poor26,29. In contrast, in the
present study, preoperative visual response assessment on
DW-MRI after nCRThad high sensitivity for the detection
of residual tumour. Moreover, the cut-off was predefined
and can therefore be used prospectively, whereas in the
aforementioned studies exploring ADC values, the optimal
cut-offs were defined retrospectively which limits their use.
A recent study11 of clinical assessment with
endoscopy/EUS, in which bite-on-bite biopsies and
fine-needle aspirates were obtained after nCRT, yielded a
specificity of 72 per cent for detection of residual tumour,
which is higher than the specificity in the present study.
However, the reported sensitivity of 77 per cent was
lower than values of over 90 per cent in the present
study. Combined with clinical examination and endoscopy,
(DW-)MRI has led to the safe selection of patients with
rectal tumours for a watch-and-wait policy after nCRT35.
Combining (DW-)MRI and endoscopy/EUS will poten-
tially result in accurate assessment of pCR after nCRT for
oesophageal cancer without missing residual disease.
The specificity for detection of residual tumour improved
from 8–25 to 42–50 per cent after adding DW-MRI in
the present study. This specificity is, however, still low.
One potential explanation for the overstaging of a pCR
as residual tumour is the occurrence of small punctate
foci of hyperintensity at the former tumour bed on
images obtained with b= 800 DW-MRI (implying
restricted diffusion, which raises the suspicion of tumour).
These false-positive foci were observed in patients with
a tumour of the gastro-oesophageal junction and may
be explained by the fact that the normal stomach wall
also shows small hyperintensities on DW-MRI, or by the
presence of radiation-induced inflammation. Prolonging
the interval between the end of radiotherapy and MRI
may result in resolution of inflammation. Furthermore,
prolonging the interval between radiation and surgery
may lead to an increase in pCR rates. A recent analysis
in oesophageal cancer36 showed that a longer interval
between nCRT and surgery increased pCR rates, without
increasing the frequency of postoperative complications.
This study had a relatively large sample size compared
with previous response studies in oesophageal cancer; how-
ever, validation in a larger cohort is required. This will
also allow subgroup analyses of squamous cell carcinoma
and adenocarcinoma. Another potential limitation is that
ADC maps were not included in the response evalua-
tion, although the readers could always refer to the T2W
images to rule out, for example, shine-through effects
caused by fluid in the oesophageal lumen. Furthermore,
lymph node response was not assessed for two reasons.
The differentiation between benign and malignant lymph
nodes on oesophageal T2W-MRI remains challenging as
non-enlarged nodes may harbour malignant cells, whereas
reactive (benign) nodes may be enlarged37,38. DW-MRI
can detect lymph nodes, but all lymph nodes have a
high signal on DW images. In patients with T0N1 rectal
cancer, MRI showed poor performance for detection of
lymphadenopathy39. Second, the field of view (FOV) of
MRI in this study focused on the primary tumour and did
not comprise the complete craniocaudal perioesophageal
area owing to imaging time restrictions. Hence, lymph
nodes outside this FOV could not be assessed. There-
fore, this study focused on tumour detection at the pri-
mary tumour bed only (TRG 1, ypT0). Other response
assessment tools are needed for the detection of lymph
node metastases after nCRT, such as EUS.
To overcome the limitations of the present study
and further increase specificity without decreasing
sensitivity for the preoperative detection of residual
tumour in oesophageal cancer, larger studies are needed.
The multicentre observational PRIDE (Preoperative
Image-guided Identification of Response to Neoadjuvant
Chemoradiotherapy in Esophageal Cancer) study40 was
initiated to explore the combination of multiple diagnostic
modalities in assessing the response of the primary tumour
and lymph nodes to chemoradiotherapy. This study aims to
develop an optimal multimodal response prediction model
focusing on clinical (endoscopy and EUS) and radiological
(MRI and FDG-PET/CT) assessment combined with
patient-specific parameters (such as circulating tumour
DNA) for oesophageal cancer.
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 596–605
on behalf of BJS Society Ltd.
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